CONTENTS


definitions

(back to contents)


schistocytes
microangiopathic hemolytic anemia (MAHA)
thrombotic microangiopathy (TMA)


causes of thrombotic microangiopathy

(back to contents)


primary thrombotic microangiopathies

TMA-associated conditions (a.k.a., “secondary TMA”)

TMA associated with rheumatologic disease
TMA associated with pregnancy – explored below.
TMA secondary to malignant hypertension
drug-induced TMA  (33841853)
infection-associated TMA
glomerular diseases associated with TMA
malignancy-associated TMA
transplantation-associated TMA
non-TMA entities to consider on the differential diagnosis

investigating the cause of TMA

(back to contents)


lab panel to evaluate the cause of a thrombotic microangiopathy

interpretation of labs to elucidate the etiology of TMA


complete blood count
coagulation labs
severity of renal failure (creatinine level)
urinalysis
ADAMTS13 tests
antinuclear antibodies (ANA)


initial empiric therapy for TMA

(back to contents)


initial treatment of TMA is a paradox

Therefore, empiric therapy must often precede definitive diagnosis.  Clinical judgement is required to rapidly assess the likelihood of TTP or C-HUS.  As laboratory data returns, the diagnosis and treatment may change (e.g., an initial empiric diagnosis of TTP may be changed to a diagnosis of probable C-HUS, after a normal ADAMTS13 level is reported).

empiric treatment for TTP with plasmapheresis and steroid

empiric eculizumab for C-HUS

introduction to TTP

(back to contents)


TTP results from the following sequence of events
congenital TTP (a.k.a., Upshaw-Schulman syndrome)

epidemiology of acquired TTP

(back to contents)



clinical presentation of TTP

(back to contents)


the classic pentad of TTP:
other symptoms:  

initial treatment of acquired TTP

(back to contents)


(#1) Fresh frozen plasma infusion while waiting for plasma exchange
(#2) plasmapheresis (a.k.a., plasma exchange)
(#3) immunosuppressive therapy
(#4) blood pressure control
(#5) avoid blood products (other than fresh frozen plasma)
(#6) Venous thromboembolism prophylaxis
(#7) antiplatelet therapy
(#8) myocardial infarction
(#9) caplacizumab


introduction to ST-HUS

(back to contents)



epidemiology and presentation of ST-HUS

(back to contents)


(#1) exposure
(#2) gastroenteritis
(#3) thrombotic microangiopathy

diagnosis of ST-HUS

(back to contents)


assays for ST-HUS
clinical value of a definitive diagnosis of ST-HUS

treatment of ST-HUS

(back to contents)



introduction to C-HUS

(back to contents)


basics
pathophysiology


clinical presentation of C-HUS

(back to contents)


(#0)  rarely, a history of C-HUS
(#1) preceding trigger
(#2) thrombotic microangiopathy


evaluation of C-HUS

(back to contents)


laboratory diagnostics are inadequate
diagnostic approach to C-HUS

treatment of C-HUS

(back to contents)



TMA in pregnancy or postpartum

(back to contents)


diagnosis of TMA in pregnancy or postpartum
differential diagnosis

management


podcast

(back to contents)


Follow us on iTunes

questions & discussion

(back to contents)


To keep this page small and fast, questions & discussion about this post can be found on another page here.

Guide to emoji hyperlinks 🔗

References

  • 09299856  Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, Tacconi F, Ascari E. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica. 1997 Jul-Aug;82(4):429-35  [PubMed]
  • 26418759  Mariotte E, Veyradier A. Thrombotic thrombocytopenic purpura: from diagnosis to therapy. Curr Opin Crit Care. 2015 Dec;21(6):593-601. doi: 10.1097/MCC.0000000000000255  [PubMed]
  • 27766045  Shen YM. Clinical evaluation of thrombotic microangiopathy: identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J. 2016 Oct 4;14(Suppl 1):19. doi: 10.1186/s12959-016-0114-0  [PubMed]
  • 28416507  Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017 May 25;129(21):2836-2846. doi: 10.1182/blood-2016-10-709857  [PubMed]
  • 29296701  Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017 Apr 6;1(10):590-600. doi: 10.1182/bloodadvances.2017005124  [PubMed]
  • 29348275  Elayoubi J, Donthireddy K, Nemakayala DR. Microangiopathies in pregnancy. BMJ Case Rep. 2018 Jan 17;2018:bcr2017221648. doi: 10.1136/bcr-2017-221648  [PubMed]
  • 29582550  Fox LC, Cohney SJ, Kausman JY, et al.  Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med J. 2018 Jun;48(6):624-636. doi: 10.1111/imj.13804  [PubMed]
  • 30031798  Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods. 2018 Oct;461:15-22. doi: 10.1016/j.jim.2018.07.006  [PubMed]
  • 30865166  Hanna RM, Barsoum M, Vandross A, Kurtz I, Burwick R. Atypical hemolytic uremic syndrome and complement blockade: established and emerging uses of complement inhibition. Curr Opin Nephrol Hypertens. 2019 May;28(3):278-287. doi: 10.1097/MNH.0000000000000499  [PubMed]
  • 30145224  Tsai HM. Atypical Hemolytic Uremic Syndrome: Beyond Hemolysis and Uremia. Am J Med. 2019 Feb;132(2):161-167. doi: 10.1016/j.amjmed.2018.08.011  [PubMed]
  • 30294946  Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial. 2019 Feb;23(1):4-21. doi: 10.1111/1744-9987.12763  [PubMed]
  • 30622684  Wiernek SL, Jiang B, Gustafson GM, Dai X. Cardiac implications of thrombotic thrombocytopenic purpura. World J Cardiol. 2018 Dec 26;10(12):254-266. doi: 10.4330/wjc.v10.i12.254  [PubMed]
  • 31588978  Azoulay E, Bauer PR, Mariotte E, et al. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med. 2019 Nov;45(11):1518-1539. doi: 10.1007/s00134-019-05736-5. Epub 2019 Oct 7. Erratum in: Intensive Care Med. 2020 Mar;46(3):570-571  [PubMed]
  • 31935318  Lee H, Kang E, Kang HG, et al.  Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020 Jan;35(1):25-40. doi: 10.3904/kjim.2019.388  [PubMed]
  • 32172817  Manrique-Caballero CL, Peerapornratana S, Formeck C, Del Rio-Pertuz G, Gomez Danies H, Kellum JA. Typical and Atypical Hemolytic Uremic Syndrome in the Critically Ill. Crit Care Clin. 2020 Apr;36(2):333-356. doi: 10.1016/j.ccc.2019.11.004  [PubMed]
  • 32259874  Blennerhassett R, Curnow J, Pasalic L. Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults. Semin Thromb Hemost. 2020 Apr;46(3):289-301. doi: 10.1055/s-0040-1708541  [PubMed]
  • 32539032  Htet Z, Karim M. Thrombotic microangiopathy with renal injury: an approach for the general physician. J R Coll Physicians Edinb. 2020 Mar;50(1):25-31. doi: 10.4997/JRCPE.2020.107  [PubMed]
  • 32757237  Paydary K, Banwell E, Tong J, Chen Y, Cuker A. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta-analysis. Transfusion. 2020 Sep;60(9):2047-2057. doi: 10.1111/trf.15954  [PubMed]
  • 32808006  Fakhouri F, Scully M, Provôt F, et al.  Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood. 2020 Nov 5;136(19):2103-2117. doi: 10.1182/blood.2020005221  [PubMed]
  • 32914582  Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2486-2495. doi: 10.1111/jth.15006  [PubMed]
  • 32914526  Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020 Oct;18(10):2496-2502. doi: 10.1111/jth.15010  [PubMed]
  • 32950988  Avila Bernabeu AI, Cavero Escribano T, Cao Vilarino M. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Nephron. 2020;144(11):537-549. doi: 10.1159/000508920  [PubMed]
  • 33179792  Liu A, Dhaliwal N, Upreti H, Kasmani J, Dane K, Moliterno A, Braunstein E, Brodsky R, Chaturvedi S. Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals. Transfusion. 2021 Jan;61(1):266-273. doi: 10.1111/trf.16188  [PubMed]
  • 33540569  Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021 Feb 2;10(3):536. doi: 10.3390/jcm10030536  [PubMed]
  • 33841853  Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J. 2020 Nov 6;14(4):1055-1066. doi: 10.1093/ckj/sfaa195  [PubMed]